Fenebrutinib an orally administered, small molecule, agammaglobulinaemia tyrosine kinase inhibitor, is being developed by Genentech for the treatment of autoimmune disorders. Reference standards of Fenebrutinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
